Justin Kao
Partner @ DFJ Growth
San Francisco, United States
Justin Kao is a Series B investor at DFJ Growth in San Francisco focused on Health Care and Medical. Justin is a Partner at Co-Founder DFJ Growth. He was a Partner at Khosla Ventures. He attended Stanford University Graduate School of Business.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Justin Kao invests in
Stages Justin Kao invests in
Countries Justin Kao invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (100%)
- Medical 2 (50%)
- Biotechnology 2 (50%)
- Hospital 1 (25%)
- Oncology 1 (25%)
Stage
- Series B 3 (75%)
- Series A 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. | $78M / Series B / Dec 04, 2025 | ||
| Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. | $225M / Series B / Jul 18, 2022 | ||
| Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-based medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org. | $40M / Series B / May 10, 2022 | ||
| Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers thatcancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics. | $40M / Series A / Jan 12, 2021 |
Co-Investors
About DFJ Growth
DFJ Growth invests in growth stage technology companies that are scaling rapidly and poised for market leadership. DFJ Growth is the later stage investing practice of iconic technology-driven businesses.
DFJ Growth Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jennifer Kodner
Talent Partner
|
|||
|
Justin Kao
Partner
|
|||
Mikowai Ashwill
Associate
|
|||
Barry Schuler
Managing Director and Partner
|
|||
Carol Wentworth
Marketing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Justin Kao invest in?
Justin Kao invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Justin Kao?
Public channels for Justin Kao include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Justin Kao last invest?
The most recent investment recorded for Justin Kao closed in Dec 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
